Biopharmaceutical Suven Life Sciences gets patents for neurodegenerative drug

NEW DELHI: Biopharmaceutical firm Suven Life Sciences today said it has been granted one patent each by Mexico and Singapore for a drug used in the treatment of neurodegenerative diseases.

Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.

In a BSE filing, the company said it has been granted "one product patent from Mexico and one product patent from Singapore corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".

These patents are valid through 2029, the company added. Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for major depressive disorders (MDD) with high unmet medical need with huge market potential globally."

With these new patents, Suven has a total of 18 granted patents from Mexico and 20 from Singapore.

"These patents are the exclusive intellectual property of Suven... products of these inventions may be outlicensed at various phases of clinical development such as phase-1 and phase-2," Suven Life Sciences said.

Suven Life Sciences was trading 1.46 per cent up at Rs 315.50 on BSE.